AIM-dt

AIM-dt (Anthracenyl Isoxazole Amide - double tail) is a novel small molecule therapeutic candidate designed for the treatment of malignant brain tumors, including glioblastoma. It belongs to the anthracenyl isoxazole amide (AIM) class of compounds, which are engineered to selectively bind and stabilize G-quadruplex (G4) telomeric DNA structures. This binding inhibits the enzymatic activity of telomerase, a key enzyme in cancer cell immortality and proliferation. Preclinical evaluations in the SNB-19 human glioblastoma cell line have shown that AIM-dt exhibits single-digit micromolar potency (IC50 of approximately 3.13 µM) and induces apoptosis. The molecule is capable of penetrating cell membranes and localizing within the nucleus to interact with genomic DNA.

Other names

anthracenyl isoxazole amide - double tail